# Bioequivalence of Two Different Drug Product Batches of Dabigatran Etexilate Following Oral Administration in Healthy Male and Female Volunteers

> **NCT02171013** · PHASE1 · COMPLETED · sponsor: **Boehringer Ingelheim** · enrollment: 66 (actual)

## Conditions studied

- Healthy

## Interventions

- **DRUG:** Dabigatran polymorph I (≈ 83%) and polymorph II (≈17%)
- **DRUG:** Dabigatran polymorph I

## Key facts

- **NCT ID:** NCT02171013
- **Lead sponsor:** Boehringer Ingelheim
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-04
- **Primary completion:** 2006-07
- **Final completion:** —
- **Target enrollment:** 66 (ACTUAL)
- **Last updated:** 2014-06-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02171013

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02171013, "Bioequivalence of Two Different Drug Product Batches of Dabigatran Etexilate Following Oral Administration in Healthy Male and Female Volunteers". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02171013. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*